Skip to main content
Top
Published in: Acta Neurologica Belgica 5/2021

01-10-2021 | COVID-19 | Original article

Lockdown effects on Parkinson’s disease during COVID-19 pandemic: a pilot study

Authors: Marika Falla, Alessandra Dodich, Costanza Papagno, Alessandro Gober, Pamela Narduzzi, Enrica Pierotti, Markus Falk, Francesca Zappini, Carlo Colosimo, Luca Turella

Published in: Acta Neurologica Belgica | Issue 5/2021

Login to get access

Abstract

The coronavirus-disease 2019 (COVID-19) outbreak precipitated prolonged lock-down measures. The subsequent social distancing, isolation, and reduction in mobility increased psychological stress, which may worsen Parkinson’s disease (PD). Therefore, telemedicine has been proposed to provide care to PD patients. To evaluate the effects of lock-down on motor and nonmotor symptoms in PD patients during the COVID-19 pandemic and the feasibility of telemedicine. Motor and nonmotor aspects were longitudinally assessed using structured questionnaires at baseline (in-person, February 2020) and at follow-up (remote web-based video, lock-down) evaluation. Of the seventeen PD patients evaluated at baseline, fourteen agreed to participate in, and completed follow-up evaluations. There was an impairment of nonmotor aspects measured with the MDS-UPDRS part I (p < 0.001) during lock-down. Nine patients participated independently in the telemedicine evaluation while five needed help from relatives. Our preliminary findings suggest an impairment of nonmotor symptoms in PD patients and support the feasibility and need for telemedicine in monitoring PD patients during the COVID-19 pandemic, to guarantee optimal assistance with reducing the burden of infection. Our findings also suggest that movement disorder clinics should be carefully considering socio-demographics and clinical features when developing telemedicine programs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tysnes OB, Storstein A (2017) Epidemiology of Parkinson’s disease. J Neural Transm (Vienna) 124:901–905CrossRef Tysnes OB, Storstein A (2017) Epidemiology of Parkinson’s disease. J Neural Transm (Vienna) 124:901–905CrossRef
3.
go back to reference Helmich RC, Bloem BR (2020) The impact of the COVID-19 pandemic on Parkinson’s disease: hidden sorrows and emerging opportunities. J Parkinson Dis 10:351–354CrossRef Helmich RC, Bloem BR (2020) The impact of the COVID-19 pandemic on Parkinson’s disease: hidden sorrows and emerging opportunities. J Parkinson Dis 10:351–354CrossRef
4.
go back to reference Hollander JE, Carr BG (2020) Virtually perfect? Telemedicine for COVID-19. N Engl J Med 382:1679–1681CrossRef Hollander JE, Carr BG (2020) Virtually perfect? Telemedicine for COVID-19. N Engl J Med 382:1679–1681CrossRef
6.
go back to reference Dorsey ER, Deuel LM, Voss TS, Finnigan K, George BP, Eason S et al (2010) Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson’s disease. Mov Disord 25:1652–1659CrossRef Dorsey ER, Deuel LM, Voss TS, Finnigan K, George BP, Eason S et al (2010) Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson’s disease. Mov Disord 25:1652–1659CrossRef
7.
go back to reference Biglan KM, Voss TS, Deuel LM, Miller D, Eason S, Fagnano M et al (2009) Telemedicine for the care of nursing home residents with Parkinson’s disease. Mov Disord 24:1073–1076CrossRef Biglan KM, Voss TS, Deuel LM, Miller D, Eason S, Fagnano M et al (2009) Telemedicine for the care of nursing home residents with Parkinson’s disease. Mov Disord 24:1073–1076CrossRef
8.
go back to reference Abdolahi A, Scoglio N, Killoran A, Dorsey ER, Biglan KM (2013) Potential reliability and validity of a modified version of the unified Parkinson’s disease rating scale that could be administered remotely. Parkinsonism Relat Disord 19:218–221CrossRef Abdolahi A, Scoglio N, Killoran A, Dorsey ER, Biglan KM (2013) Potential reliability and validity of a modified version of the unified Parkinson’s disease rating scale that could be administered remotely. Parkinsonism Relat Disord 19:218–221CrossRef
9.
go back to reference Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601CrossRef Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601CrossRef
10.
go back to reference Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442CrossRef Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442CrossRef
11.
go back to reference Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653CrossRef Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653CrossRef
12.
go back to reference Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I et al (2005) The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699CrossRef Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I et al (2005) The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699CrossRef
13.
go back to reference Cohen S, Kamarck T, Mermelstein R (1983) A global measure of perceived stress. J Health Soc Behav 24:385–396CrossRef Cohen S, Kamarck T, Mermelstein R (1983) A global measure of perceived stress. J Health Soc Behav 24:385–396CrossRef
14.
go back to reference Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al (2008) Movement disorder society UPDRS revision task force. Movement disorder society-sponsored revision of the unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129–2170CrossRef Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al (2008) Movement disorder society UPDRS revision task force. Movement disorder society-sponsored revision of the unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129–2170CrossRef
15.
go back to reference Santangelo G, Falco F, D’Iorio A, Cuoco S, Raimo S, Amboni M et al (2016) Anxiety in early Parkinson’s disease: validation of the Italian observer-rated version of the Parkinson Anxiety Scale (OR-PAS). J Neurol Sci 367:158–161CrossRef Santangelo G, Falco F, D’Iorio A, Cuoco S, Raimo S, Amboni M et al (2016) Anxiety in early Parkinson’s disease: validation of the Italian observer-rated version of the Parkinson Anxiety Scale (OR-PAS). J Neurol Sci 367:158–161CrossRef
16.
go back to reference Yesavage JA, Brink TL, Rose TL, Lum D, Huang V, Adey M et al (1982-1983) Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17:37–49 Yesavage JA, Brink TL, Rose TL, Lum D, Huang V, Adey M et al (1982-1983) Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17:37–49
17.
go back to reference Marin RS, Biedrzycki RC, Firinciogullari S (1991) Reliability and validity of the apathy evaluation scale. Psychiatry Res 38:143–162CrossRef Marin RS, Biedrzycki RC, Firinciogullari S (1991) Reliability and validity of the apathy evaluation scale. Psychiatry Res 38:143–162CrossRef
18.
go back to reference Lubben J (1998) Assessing social networks among elderly populations. Fam Commun Health J Health Promot Maintenance 11:42–52 Lubben J (1998) Assessing social networks among elderly populations. Fam Commun Health J Health Promot Maintenance 11:42–52
19.
go back to reference Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N (1997) The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 26:353–357CrossRef Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N (1997) The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 26:353–357CrossRef
20.
go back to reference Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res 4:241–248CrossRef Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res 4:241–248CrossRef
21.
go back to reference Yardley L, Beyer N, Hauer K, Kempen G, Piot-Ziegler C, Todd C (2005) Development and initial validation of the falls efficacy scale-international (FES-I). Age Ageing 34:614–619CrossRef Yardley L, Beyer N, Hauer K, Kempen G, Piot-Ziegler C, Todd C (2005) Development and initial validation of the falls efficacy scale-international (FES-I). Age Ageing 34:614–619CrossRef
22.
go back to reference Powell LE, Myers AM (1995) The activities-specific balance confidence (ABC) scale. J Gerontol Med Sci 50:28–34CrossRef Powell LE, Myers AM (1995) The activities-specific balance confidence (ABC) scale. J Gerontol Med Sci 50:28–34CrossRef
23.
go back to reference Nieuwboer A, Rochester L, Herman T, Vandenberghe W, Emil GE, Thomaes T et al (2009) Reliability of the new freezing of gait questionnaire: agreement between patients with Parkinson’s disease and their careers. Gait Posture 30:459–463CrossRef Nieuwboer A, Rochester L, Herman T, Vandenberghe W, Emil GE, Thomaes T et al (2009) Reliability of the new freezing of gait questionnaire: agreement between patients with Parkinson’s disease and their careers. Gait Posture 30:459–463CrossRef
24.
go back to reference Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123CrossRef Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123CrossRef
26.
go back to reference Jianjun L (2007) A two-step rejection procedure for testing multiple hypotheses. J Stat Plan Infer 138:1521–1527 Jianjun L (2007) A two-step rejection procedure for testing multiple hypotheses. J Stat Plan Infer 138:1521–1527
28.
go back to reference Lin CH, Lin JW, Liu YC, Chang CH, Wu RM (2015) Risk of Parkinson’s disease following anxiety disorders: a nationwide population-based cohort study. Eur J Neurol 22:1280–1287CrossRef Lin CH, Lin JW, Liu YC, Chang CH, Wu RM (2015) Risk of Parkinson’s disease following anxiety disorders: a nationwide population-based cohort study. Eur J Neurol 22:1280–1287CrossRef
29.
go back to reference Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8:464–474CrossRef Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8:464–474CrossRef
30.
go back to reference Marin RS, Fogel BS, Hawkins J, Duffy J, Krupp B (1995) Apathy: a treatable syndrome. J Neuropsychiatry Clin Neurosci 7:23–30CrossRef Marin RS, Fogel BS, Hawkins J, Duffy J, Krupp B (1995) Apathy: a treatable syndrome. J Neuropsychiatry Clin Neurosci 7:23–30CrossRef
31.
go back to reference McKinlay A, Grace RC, Dalrymple-Alford JC, Anderson TJ, Fink J, Roger D (2008) Neuropsychiatric problems in Parkinson’s disease: comparisons between self and caregiver report. Aging Ment Health 12:647–653CrossRef McKinlay A, Grace RC, Dalrymple-Alford JC, Anderson TJ, Fink J, Roger D (2008) Neuropsychiatric problems in Parkinson’s disease: comparisons between self and caregiver report. Aging Ment Health 12:647–653CrossRef
32.
go back to reference Radakovic R, Davenport R, Starr JM, Abrahams S (2018) Apathy dimensions in Parkinson’s disease. Int J Geriatr Psychiatry 33:151–158CrossRef Radakovic R, Davenport R, Starr JM, Abrahams S (2018) Apathy dimensions in Parkinson’s disease. Int J Geriatr Psychiatry 33:151–158CrossRef
33.
go back to reference Schiehser DM, Liu L, Lessig SL, Song DD, Obtera KM, Burke Iii MM et al (2013) Predictors of discrepancies in Parkinson’s disease patient and caregiver ratings of apathy, disinhibition, and executive dysfunction before and after diagnosis. J Int Neuropsychol Soc 19:295–304CrossRef Schiehser DM, Liu L, Lessig SL, Song DD, Obtera KM, Burke Iii MM et al (2013) Predictors of discrepancies in Parkinson’s disease patient and caregiver ratings of apathy, disinhibition, and executive dysfunction before and after diagnosis. J Int Neuropsychol Soc 19:295–304CrossRef
34.
go back to reference Valentino V, Iavarone A, Amboni M, Moschiano F, Picillo M, Petretta V et al (2018) Apathy in Parkinson’s disease: differences between caregiver’s report and self-evaluation. Funct Neurol 33:31–35CrossRef Valentino V, Iavarone A, Amboni M, Moschiano F, Picillo M, Petretta V et al (2018) Apathy in Parkinson’s disease: differences between caregiver’s report and self-evaluation. Funct Neurol 33:31–35CrossRef
35.
go back to reference Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23:183–189CrossRef Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23:183–189CrossRef
36.
go back to reference Fasano A, Cereda E, Barichella M, Cassani E, Ferri V, Zecchinelli AL, Pezzoli G (2020) COVID-19 in Parkinson’s disease patients living in Lombardy, Italy. Mov Disord 35:1089–1093CrossRef Fasano A, Cereda E, Barichella M, Cassani E, Ferri V, Zecchinelli AL, Pezzoli G (2020) COVID-19 in Parkinson’s disease patients living in Lombardy, Italy. Mov Disord 35:1089–1093CrossRef
Metadata
Title
Lockdown effects on Parkinson’s disease during COVID-19 pandemic: a pilot study
Authors
Marika Falla
Alessandra Dodich
Costanza Papagno
Alessandro Gober
Pamela Narduzzi
Enrica Pierotti
Markus Falk
Francesca Zappini
Carlo Colosimo
Luca Turella
Publication date
01-10-2021
Publisher
Springer International Publishing
Published in
Acta Neurologica Belgica / Issue 5/2021
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-021-01732-z

Other articles of this Issue 5/2021

Acta Neurologica Belgica 5/2021 Go to the issue